These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 8225595)

  • 21. Treatment of experimental pyelonephritis in the monkey.
    Roberts JA; Kaack MB; Baskin G
    J Urol; 1990 Jan; 143(1):150-4. PubMed ID: 2403597
    [TBL] [Abstract][Full Text] [Related]  

  • 22. P-fimbriated Escherichia coli in adults with renal scarring and pyelonephritis.
    Jacobson SH
    Acta Med Scand Suppl; 1986; 713():1-64. PubMed ID: 2880464
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Experimental pyelonephritis in the monkey. VII. Ascending pyelonephritis in the absence of vesicoureteral reflux.
    Roberts JA; Suarez GM; Kaack B; Kallenius G; Svenson SB
    J Urol; 1985 Jun; 133(6):1068-75. PubMed ID: 2860250
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Divalent flagellin immunotherapy provides homologous and heterologous protection in experimental urinary tract infections in mice.
    Sabharwal N; Chhibber S; Harjai K
    Int J Med Microbiol; 2016 Jan; 306(1):29-37. PubMed ID: 26655680
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthetic peptides protect against infection in a model of experimental pyelonephritis in mice.
    Schmidt MA; O'Hanley P; Schoolnik GK
    Ann Sclavo Collana Monogr; 1986; 3(1-2):389-98. PubMed ID: 3322342
    [No Abstract]   [Full Text] [Related]  

  • 26. The effect of active immunisation on ascending pyelonephritis in the rat.
    Radford NJ; Chick S; Ling R; Coles GA; Asscher AW
    J Pathol; 1974 Mar; 112(3):169-75. PubMed ID: 4601025
    [No Abstract]   [Full Text] [Related]  

  • 27. Evaluation of a LPS-based glycoconjugate vaccine against bovine Escherichia coli mastitis: Formation of LPS Abs in cows after immunization with E. coli core oligosaccharides conjugated to hemocyanine.
    Brade L; Hensen S; Brade H
    Innate Immun; 2013; 19(4):368-77. PubMed ID: 23112009
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protection against experimental pyelonephritis by antibodies to pili.
    Silverblatt FJ; Weinstein R; Rene P
    Scand J Infect Dis Suppl; 1982; 33():79-82. PubMed ID: 6127805
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical pyelonephritis and focal renal scarring. A selected review of pathogenesis, prevention, and prognosis.
    Winberg J; Bollgren I; Källenius G; Möllby R; Svenson SB
    Pediatr Clin North Am; 1982 Aug; 29(4):801-14. PubMed ID: 6125926
    [No Abstract]   [Full Text] [Related]  

  • 30. Protective anti-idiotype antibodies in the primate model of pyelonephritis.
    Kaack MB; Martin LN; Svenson SB; Baskin G; Steele RH; Roberts JA
    Infect Immun; 1993 Jun; 61(6):2289-95. PubMed ID: 8099064
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protection by a polyvalent vaccine against challenge infection and pyelonephritis.
    Kruze D; Biro K; Holzbecher K; Andrial M; Bossart W
    Urol Res; 1992; 20(2):177-81. PubMed ID: 1553795
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protection against acute, ascending pyelonephritis caused by Escherichia coli in rats, using isolated capsular antigen conjugated to bovine serum albumin.
    Kaijser B; Larsson P; Olling S; Schneerson R
    Infect Immun; 1983 Jan; 39(1):142-6. PubMed ID: 6337094
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Brucellosis: Improved Diagnostics and Vaccine Insights from Synthetic Glycans.
    Bundle DR; McGiven J
    Acc Chem Res; 2017 Dec; 50(12):2958-2967. PubMed ID: 29219305
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pyelonephritis. XIV. Effect of immunization on experimental Escherichia coli pyelonephritis.
    Montgomerie JZ; Kalmanson GM; Hubert EG; Guze LB
    Infect Immun; 1972 Sep; 6(3):330-4. PubMed ID: 4564890
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Preliminary results of the vaccine treatment of chronic pyelonephritis in animal experiments].
    Straube E; Broschewitz U; Schill H; Naumann G
    Z Urol Nephrol; 1984 Jul; 77(7):401-5. PubMed ID: 6385543
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety, immunogenicity, and efficacy in monkeys and humans of invasive Escherichia coli K-12 hybrid vaccine candidates expressing Shigella flexneri 2a somatic antigen.
    Kotloff KL; Herrington DA; Hale TL; Newland JW; Van De Verg L; Cogan JP; Snoy PJ; Sadoff JC; Formal SB; Levine MM
    Infect Immun; 1992 Jun; 60(6):2218-24. PubMed ID: 1587589
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Experimental Escherichia coli ascending pyelonephritis in rats: changes in bacterial properties and the immune response to surface antigens.
    Mattsby-Baltzer I; Hanson LA; Kaijser B; Larsson P; Olling S; Svanborg-Edén C
    Infect Immun; 1982 Feb; 35(2):639-46. PubMed ID: 7035369
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of immunization with ethanol-soluble enterobacterial common antigen on in vivo bacterial clearance and hematogenous pyelonephritis.
    Frentz G; Domingue G
    Proc Soc Exp Biol Med; 1973 Jan; 142(1):246-52. PubMed ID: 4566760
    [No Abstract]   [Full Text] [Related]  

  • 39. Serological response to the P fimbriae of uropathogenic Escherichia coli in pyelonephritis.
    de Ree JM; van den Bosch JF
    Infect Immun; 1987 Sep; 55(9):2204-7. PubMed ID: 2887515
    [TBL] [Abstract][Full Text] [Related]  

  • 40. P-fimbriae vaccines. I. Cross reactive antibodies to heterologous P-fimbriae.
    Kaack MB; Pere A; Korhonen TK; Svenson SB; Roberts JA
    Pediatr Nephrol; 1989 Oct; 3(4):386-90. PubMed ID: 2577146
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.